3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
8
Neoplasms
4
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Gliosarcoma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Doxorubicin
14
Radiotherapy
10
Ifosfamide
10
Trabectedin
7
pazopanib
4
Imatinib Mesylate
3
Filgrastim
3
Etoposide
3
Cyclophosphamide
3
Chemotherapy, Adjuvant
3
temsirolimus
2
romidepsin
2
ribociclib
2
pegfilgrastim
2
eribulin
2
cixutumumab
2
brigimadlin
2
belinostat
2
Vincristine
2
Sunitinib
2
Radiotherapy, Conformal
2
Gemcitabine
2
Epirubicin
2
Dexamethasone
2
Dactinomycin
2
Carboplatin
2
soblidotin
1
sitravatinib
1
siremadlin
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Liposarcoma
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts